$VRDN filed an 8-K with results (Item 2.02) at 7:11 AM ET on Wed, Nov 4.
Vote
VRDN
Viridian Therapeutics, Inc.$26.62CS band Caution
+1.47 (+5.86%) TodayNov 4, 10:43 AM ET
About VRDN
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Board
Community opinions, not advice. Posts with a target get a receipt. How receipts work ›